{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:21:11Z","timestamp":1787473271541,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prrv.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:00:32Z","timestamp":1774465232000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Keeping up with CFTR modulator eligibility"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5217-2256","authenticated-orcid":false,"given":"Rebecca","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2026.03.003_b0005","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2026.03.003_b0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR modulators on longitudinal cystic fibrosis survival and mortality: review and secondary analysis","volume":"11","author":"Rubin","year":"2025","journal-title":"Pulm Ther"},{"key":"10.1016\/j.prrv.2026.03.003_b0030","unstructured":"Cystic Fibrosis Trust. Registry Annual Report, https:\/\/www.cysticfibrosis.org.uk\/about-us\/uk-cf-registry\/reporting-and-resources; [accessed 10Feb2026]."},{"key":"10.1016\/j.prrv.2026.03.003_b0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.prrv.2026.03.003_b0040","unstructured":"Zolin A, Adamoli A, Bakkeheim E. ECFSPR annual report 2022, https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2022_ECFSPR_20240603.pdf; 2024 [accessed 10Feb2026]."},{"key":"10.1016\/j.prrv.2026.03.003_b0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009100","article-title":"Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies","volume":"16","author":"Joynt","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.prrv.2026.03.003_b0055","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"PNAS"},{"key":"10.1016\/j.prrv.2026.03.003_b0060","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prrv.2026.03.003_b0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12955-015-0293-6","article-title":"Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial","volume":"13","author":"Quittner","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.prrv.2026.03.003_b0070","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0080","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0085","doi-asserted-by":"crossref","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.prrv.2026.03.003_b0090","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2026.03.003_b0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0125","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single-breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.03.003_b0135","unstructured":"CFTR2. CFTR2: Clinical and Functional Translation of CFTR, https:\/\/cftr2.org; [accessed 20Feb2026]."},{"key":"10.1016\/j.prrv.2026.03.003_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. food and drug administration\u2019s experience with ivacaftor in cystic fibrosis: establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2026.03.003_b0145","unstructured":"NHS England. Updated Commissioning Statement Ivacaftor, tezacaftor\/ivacaftor, lumacaftor\/ivacaftor and elexacaftor\/tezacaftor\/ivacaftor for licensed and off-label use in patients with cystic fibrosis who have named mutations. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/03\/Commissioning-Statement-CF-modulator-therapies-for-Cystic-Fibrosis-UPDATED-2022.pdf; 2022 [accessed 10Feb2026]."},{"key":"10.1016\/j.prrv.2026.03.003_b0150","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prrv.2026.03.003_b0155","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0160","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Kaftrio assessment report, https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/kaftrio-h-c-005269-ws-2551-epar-assessment-report-variation_en.pdf; 2025 [accessed 10Feb2026]."},{"key":"10.1016\/j.prrv.2026.03.003_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.prrv.2026.03.003_b0170","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","volume":"23","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0175","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.prrv.2026.03.003_b0185","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic Drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prrv.2026.03.003_b0190","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70245","article-title":"Elexacaftor\/tezacaftor\/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis","volume":"18","author":"Truong","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.prrv.2026.03.003_b0195","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jcf.2025.03.008","article-title":"Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study","volume":"24","author":"Vonk","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0200","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02490-2024","article-title":"Real-world monitoring of elexacaftor\/tezacaftor\/ivacaftor trough concentrations in adults with cystic fibrosis","volume":"65","author":"Magnas","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.03.003_b0205","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of elexacaftor\u2013tezacaftor\u2013ivacaftor treatment in individuals with cystic fibrosis and CFTR N1303K in the USA: a prospective, multicentre, open-label, single-arm trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/jpm12040632","article-title":"Theratyping of the rare CFTR variants E193K and R334W in rectal organoid-derived epithelial monolayers","volume":"12","author":"Ciciriello","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0215","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ijms25010114","article-title":"The effect of complex alleles of the CFTR gene on the clinical manifestations of cystic fibrosis and the effectiveness of targeted therapy","volume":"25","author":"Krasnova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prrv.2026.03.003_b0220","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR-Modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prrv.2026.03.003_b0225","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.3390\/ijms262311742","article-title":"L467F;F508del complex allele in a heterozygous state with CFTRdele2,3: what to expect from CFTR modulators?","volume":"26","author":"Kondratyeva","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prrv.2026.03.003_b0230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/jhg.2016.34","article-title":"A commentary on the novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies","volume":"61","author":"Lucarelli","year":"2016","journal-title":"J Hum Genet"},{"key":"10.1016\/j.prrv.2026.03.003_b0235","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3390\/jpm12091421","article-title":"Modulator therapy in cystic fibrosis patients with cis variants in F508del complex allele: a short-term observational case series","volume":"12","author":"Terlizzi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0240","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.3390\/ijms24065199","article-title":"CFTR modulators rescue the activity of CFTR in colonoids expressing the complex allele p.[R74W;V201M;D1270N]\/dele22_24","volume":"24","author":"Kleinfelder","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.prrv.2026.03.003_b0245","first-page":"4590","article-title":"Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics","volume":"25","author":"Strug","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.prrv.2026.03.003_b0250","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3389\/fphar.2018.00828","article-title":"SLC26A9 gene is associated with lung function response to ivacaftor in patients with cystic fibrosis","volume":"9","author":"Corvol","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.prrv.2026.03.003_b0255","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jcf.2021.02.007","article-title":"SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR","volume":"20","author":"Eastman","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0260","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201304-0733OC","article-title":"Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function","volume":"188","author":"Raju","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0265","doi-asserted-by":"crossref","first-page":"L324","DOI":"10.1152\/ajplung.00328.2024","article-title":"Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis","volume":"328","author":"Wisniewski","year":"2025","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.prrv.2026.03.003_b0270","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcf.2025.05.002","article-title":"Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis","volume":"24","author":"Harris","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0275","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcf.2016.11.008","article-title":"Biological variability of the sweat chloride in diagnostic sweat tests: a retrospective analysis","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0285","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcf.2021.06.013","article-title":"A short extension to multiple breath washout provides additional signal of distal airway disease in people with CF: a pilot study","volume":"21","author":"Short","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0290","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00006-2020","article-title":"An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter","volume":"56","author":"Davies","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.03.003_b0295","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor\/Tezacaftor\/Ivacaftor treatment in people with cystic fibrosis aged 12 years and older \u2013 the RECOVER Trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00408-024-00768-1","article-title":"Lung Clearance Index improves in people with cystic fibrosis not achieving a clinical important difference in forced expiratory volume in one second after elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"203","author":"Dacc\u00f2","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.prrv.2026.03.003_b0305","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00286-2023","article-title":"Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease","volume":"62","author":"Bayfield","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.03.003_b0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiol.2018181148","article-title":"Three-dimensional isotropic functional imaging of cystic fibrosis using oxygen-enhanced MRI: comparison with hyperpolarized 3He MRI","volume":"290","author":"Zha","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.prrv.2026.03.003_b0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.003_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.prrv.2026.03.003_b0325","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcf.2024.04.016","article-title":"Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe organoid study","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2026.03.003_b0330","unstructured":"Fair Therapeutics B.V. Press release Fair Therapeutics B.V. announces final results CHOICES HIT-CF trial: clinical effect proportional to in-vitro effect, https:\/\/www.fairtherapeutics.com\/news; 2025 [accessed 10Feb2026]."}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T07:48:26Z","timestamp":1787471306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"alternative-id":["S1526054226000242"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.03.003","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Keeping up with CFTR modulator eligibility","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}